A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Ongoing, no longer enrolling
Registry enrollment: 864 participants
Study ages: 18 Years to 55 Years
Results posted Feb 17, 2026
Read trial record and resultsChecked Nov 12, 2026